Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-02-24 @ 1:11 PM
Study NCT ID:
NCT01728220
Status:
COMPLETED
Last Update Posted:
2023-02-27
First Post:
2012-11-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006976', 'term': 'Hypertension, Pulmonary'}, {'id': 'D029424', 'term': 'Pulmonary Disease, Chronic Obstructive'}], 'ancestors': [{'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 159}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-07', 'dispFirstSubmitDate': '2015-01-30', 'completionDateStruct': {'date': '2014-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-17', 'studyFirstSubmitDate': '2012-11-13', 'dispFirstSubmitQcDate': '2015-01-30', 'studyFirstSubmitQcDate': '2012-11-13', 'dispFirstPostDateStruct': {'date': '2015-02-18', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2023-02-27', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2012-11-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in pulmonary arterial systolic pressure (PASP) from Baseline after treatment with iNO (measured by 2D transthoracic echocardiography with Doppler)', 'timeFrame': 'baseline to end of treatment (1 day)'}], 'secondaryOutcomes': [{'measure': 'The secondary outcome is the occurrence of a decrease ≥ 5 mm Hg of partial pressure of oxygen in arterial blood (PaO2) from Baseline after treatment with iNO', 'timeFrame': 'baseline to end of treatment (1 day)'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Inhaled nitric oxide (iNO)', 'Pulmonary hypertension (PH)', 'Chronic obstructive pulmonary disease (COPD)', 'Long term oxygen therapy (LTOT)'], 'conditions': ['Pulmonary Hypertension', 'Chronic Obstructive Pulmonary Disease']}, 'descriptionModule': {'briefSummary': 'This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C vs. placebo in subjects with World Health Organization (WHO) Group 3 pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD) on Long Term Oxygen Therapy (LTOT).', 'detailedDescription': 'This two-part study is designed to confirm the dose of inhaled nitric oxide (NO), administered through an investigational pulsed delivery device (INOpulse® DS-C) that results in decreased pulmonary arterial systolic pressure (PASP) without significantly affecting systemic oxygenation.\n\nIn Part A, 80 subjects will be randomized to 1of 4 treatment groups in a 1:1:1:1 ratio (with 20 subjects in each treatment group). Subjects assigned to an iNO group will receive pulsed iNO at a dose of 0.003 mg/kg IBW/hr, 0.010 mg/kg IBW/hr, or 0.015 mg/kg IBW/hr, with a set pulse width (PW) of 260 milliseconds (ms). Part A subjects assigned to the placebo group will receive nitrogen (N2) at a randomly assigned device setting of 0.003, 0.010 or 0.015 mg/kg IBW/hr with a set PW of 260 ms.\n\nSubjects who were randomized in Part A are permitted to participate in Part B of the study. Subjects will need to be re-screened and re-randomized for Part B participation.\n\nIn Part B, 60 subjects will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (with 20 subjects in each treatment group). Subjects assigned to an iNO group will receive pulsed iNO at either 0.030 mg/kg IBW/hr or 0.075 mg/kg IBW/hr, with a set PW of 260 ms. Part B subjects assigned to placebo will receive N2 at a randomly assigned device setting of 0.030 mg/kg IBW/hr or 0.075 mg/kg IBW/hr with a set PW of 260 ms.\n\nPart B will use a skewed block randomization scheme with 10 blocks of 6 subjects as follows:\n\n* Blocks 1-3: 3 subjects at 0.030 mg/kg IBW/hr, 1 subject at 0.075 mg/kg IBW/hr, and 2 subjects randomly assigned to placebo either 0.030 or 0.075 mg/kg IBW/hr\n* Blocks 4-7: 2 subjects at 0.030 mg/kg IBW/hr, 2 subjects at 0.075 mg/kg IBW/hr, and 2 subjects randomly assigned to placebo either 0.030 or 0.075 mg/kg IBW/hr\n* Blocks 8-10: 1 subject at 0.030 mg/kg IBW/hr, 3 subjects at 0.075 mg/kg IBW/hr, and 2 subjects randomly assigned to placebo either 0.030 or 0.075 mg/kg IBW/hr'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Former smokers with at least 10 pack-years of tobacco cigarette smoking history before study entry and who have stopped smoking ≥ 1 month prior to enrollment\n2. Age ≥ 40 years, ≤ 80 years\n3. A confirmed diagnosis of COPD by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria\n4. A post-bronchodilatory forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \\< 0.7 and a FEV1 \\< 60% predicted (values obtained within 6 months prior to screening can be used unless obtained within ± 7 days of an exacerbation; otherwise, the test must be performed during screening)\n5. Receiving LTOT for ≥ 3 months and ≥ 10 hours per day as determined by history\n6. Echocardiogram with technical adequacy demonstrating tricuspid regurgitation velocity (TRV) ≥ 2.9 m/s at Screening, as determined by a blinded central echocardiography laboratory\n7. Females of childbearing potential must have a negative pre-treatment urine pregnancy test\n8. Signed informed consent prior to the initiation of any study mandated procedures or assessments\n\nExclusion criteria:\n\nSubjects who meet any of the following criteria are not eligible for enrollment:\n\n1. Positive urine cotinine test\n2. Currently using, or having used within the past month, a nicotine patch\n3. A diagnosis of asthma or other non-COPD respiratory disease, in the opinion of the Investigator\n4. Lack of patency of nares upon physical examination\n5. Experienced an exacerbation requiring start of or increase in systemic oral corticosteroid therapy and/or hospitalization during the last month (ATS COPD Guidelines 2004)\n6. Left ventricular dysfunction as measured by:\n\n 1. Screening echocardiographic evidence of left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) \\< 40%), or\n 2. Screening echocardiographic evidence of left ventricular diastolic dysfunction \\> moderate (i.e., \\> Grade 2), or\n 3. Any history of pulmonary capillary wedge pressure (PCWP), left atrial pressure (LAP) or left ventricular end diastolic pressure (LVEDP) \\> 18 mm Hg as measured during cardiac catheterization within the past 6 months unless documented to have resolved by a subsequent cardiac catheterization\n7. Clinically significant valvular heart disease that may contribute to PH, including mild or greater aortic valvular disease (aortic stenosis or regurgitation) and/or moderate or greater mitral valve disease (mitral stenosis or regurgitation), or status post mitral valve replacement\n8. Use within 30 days of screening or current use of approved PH medications such as sildenafil or bosentan (use of Cialis® or Viagra® for erectile dysfunction is permitted)\n9. Use of investigational drugs or devices within 30 days prior to enrollment into the study\n10. Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study'}, 'identificationModule': {'nctId': 'NCT01728220', 'briefTitle': 'Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bellerophon'}, 'officialTitle': 'A Placebo-Controlled, Double-Blind, Parallel, Randomized, Two-Part, Clinical Dose-Confirming Study Of Pulsed, Inhaled Nitric Oxide (iNO) In Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) On Long Term Oxygen Therapy (LTOT) INHALE 1', 'orgStudyIdInfo': {'id': 'IK-7002-COPD-201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)', 'description': 'Inhaled NO using 3.0 mg/L \\[2440 ppm\\] NO minicylinder delivered via INOpulse® DS-C device', 'interventionNames': ['Combination Product: Inhaled NO delivered via INOpulse DS-C Device']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)', 'description': 'Inhaled NO using 3.0 mg/L \\[2440 ppm\\] NO minicylinder delivered via INOpulse® DS-C device', 'interventionNames': ['Combination Product: Inhaled NO delivered via INOpulse DS-C Device']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)', 'description': 'Inhaled NO using 6.0 mg/L \\[4880 ppm\\] NO minicylinder delivered via INOpulse® DS-C device', 'interventionNames': ['Combination Product: Inhaled NO delivered via INOpulse DS-C Device']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)', 'description': 'Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device', 'interventionNames': ['Combination Product: Placebo delivered via INOpulse DS-C Device']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)', 'description': 'Inhaled NO using 6.0 mg/L \\[4880 ppm\\] NO minicylinder delivered via INOpulse® DS-C device', 'interventionNames': ['Combination Product: Inhaled NO delivered via INOpulse DS-C Device']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)', 'description': 'Inhaled NO using 6.0 mg/L \\[4880 ppm\\] NO minicylinder delivered via INOpulse® DS-C device', 'interventionNames': ['Combination Product: Inhaled NO delivered via INOpulse DS-C Device']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)', 'description': 'Placebo using 99.999% N2 minicylinder delivered via INOpulse® DS-C device', 'interventionNames': ['Combination Product: Placebo delivered via INOpulse DS-C Device']}], 'interventions': [{'name': 'Inhaled NO delivered via INOpulse DS-C Device', 'type': 'COMBINATION_PRODUCT', 'description': 'Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.', 'armGroupLabels': ['Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)', 'Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)', 'Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)', 'Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)', 'Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)']}, {'name': 'Placebo delivered via INOpulse DS-C Device', 'type': 'COMBINATION_PRODUCT', 'description': 'Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.', 'armGroupLabels': ['Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)', 'Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35501', 'city': 'Jasper', 'state': 'Alabama', 'country': 'United States', 'facility': 'Jasper Summit Research LLC', 'geoPoint': {'lat': 33.83122, 'lon': -87.27751}}, {'zip': '86001', 'city': 'Flagstaff', 'state': 'Arizona', 'country': 'United States', 'facility': 'Clinical Trial Connection', 'geoPoint': {'lat': 35.19807, 'lon': -111.65127}}, {'zip': '85006', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': 'Pulmonary Associates P.A.', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '92663', 'city': 'Newport Beach', 'state': 'California', 'country': 'United States', 'facility': 'Radin Cardiovascular Medical Associates', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '06810', 'city': 'Danbury', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Western Connecticut Medical Group PC', 'geoPoint': {'lat': 41.39482, 'lon': -73.45401}}, {'zip': '06708', 'city': 'Waterbury', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Waterbury Pulmonary Associates', 'geoPoint': {'lat': 41.55815, 'lon': -73.0515}}, {'zip': '33756', 'city': 'Clearwater', 'state': 'Florida', 'country': 'United States', 'facility': 'Bay Area Chest Physicians', 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'zip': '33316', 'city': 'Fort Lauderdale', 'state': 'Florida', 'country': 'United States', 'facility': 'Gary J. Richmond, MD, PA', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'zip': '32204', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'East Coast Institute for Research', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '34741', 'city': 'Kissimmee', 'state': 'Florida', 'country': 'United States', 'facility': 'Pulmonary Disease Specialists PA', 'geoPoint': {'lat': 28.30468, 'lon': -81.41667}}, {'zip': '33015', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'San Marcus Research Clinic Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33126', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'St. Paul Medical Research Center Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33140', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'IMIC, Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33144', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Elite Clinical Research', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33165', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'South Florida Research Phase I-IV', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33173', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Health & Life Research Solutions Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '34653', 'city': 'New Port Richey', 'state': 'Florida', 'country': 'United States', 'facility': 'Advanced Research Institute, Inc.', 'geoPoint': {'lat': 28.24418, 'lon': -82.71927}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Central Florida Pulmonary Group, P.A.', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33872', 'city': 'Sebring', 'state': 'Florida', 'country': 'United States', 'facility': 'Bassette Medical Research Inc.', 'geoPoint': {'lat': 27.49559, 'lon': -81.44091}}, {'zip': '33710', 'city': 'St. Petersburg', 'state': 'Florida', 'country': 'United States', 'facility': 'Research Alliance', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'zip': '33319', 'city': 'Tamarac', 'state': 'Florida', 'country': 'United States', 'facility': 'Concept Clinical Trials, LLC', 'geoPoint': {'lat': 26.21286, 'lon': -80.24977}}, {'zip': '33414', 'city': 'Wellington', 'state': 'Florida', 'country': 'United States', 'facility': 'Axcess Medical Research', 'geoPoint': {'lat': 26.65868, 'lon': -80.24144}}, {'zip': '32789', 'city': 'Winter Park', 'state': 'Florida', 'country': 'United States', 'facility': 'Florida Premier Research Institute', 'geoPoint': {'lat': 28.6, 'lon': -81.33924}}, {'zip': '30513', 'city': 'Blue Ridge', 'state': 'Georgia', 'country': 'United States', 'facility': 'River Birch Research Alliance LLC', 'geoPoint': {'lat': 34.86397, 'lon': -84.32409}}, {'zip': '30114', 'city': 'Canton', 'state': 'Georgia', 'country': 'United States', 'facility': 'Medical Associates of North Georgia', 'geoPoint': {'lat': 34.23676, 'lon': -84.49076}}, {'zip': '66606', 'city': 'Topeka', 'state': 'Kansas', 'country': 'United States', 'facility': 'Veritas Clinical Specialties, Ltd', 'geoPoint': {'lat': 39.04833, 'lon': -95.67804}}, {'zip': '42101', 'city': 'Bowling Green', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Graves-Gilbert Clinic', 'geoPoint': {'lat': 36.99032, 'lon': -86.4436}}, {'zip': '40218', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Kentucky Research Group', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '70006', 'city': 'Metairie', 'state': 'Louisiana', 'country': 'United States', 'facility': 'MedPharmics LLC', 'geoPoint': {'lat': 29.98409, 'lon': -90.15285}}, {'zip': '48060', 'city': 'Port Huron', 'state': 'Michigan', 'country': 'United States', 'facility': 'Physician HealthCare Network, PC', 'geoPoint': {'lat': 42.97086, 'lon': -82.42491}}, {'zip': '10461', 'city': 'The Bronx', 'state': 'New York', 'country': 'United States', 'facility': 'Montefiore Medical Center-Weiler Division', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '28207', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'American Health Research', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'University Hospitals Case Medical Center', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '19140', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Temple Lung Center Pulmonary & Critical Care Medicine', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '29406', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Lowcountry Lung and Critical Care', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '29201', 'city': 'Columbia', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Neem Research Group Inc', 'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}, {'zip': '29340', 'city': 'Gaffney', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Gaffney Pharmaceutical Research', 'geoPoint': {'lat': 35.07179, 'lon': -81.64982}}, {'zip': '29615', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Greenville Pharmaceutical Research', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '29732', 'city': 'Rock Hill', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Clinical Research of Rock Hill', 'geoPoint': {'lat': 34.92487, 'lon': -81.02508}}, {'zip': '29303', 'city': 'Spartanburg', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Spartanburg Medical Research', 'geoPoint': {'lat': 34.94957, 'lon': -81.93205}}, {'zip': '77479', 'city': 'Sugar Land', 'state': 'Texas', 'country': 'United States', 'facility': 'Pioneer Research Solutions, Inc.', 'geoPoint': {'lat': 29.61968, 'lon': -95.63495}}, {'zip': '23225', 'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': 'Pulmonary Associates of Richmond Inc', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '99352', 'city': 'Richland', 'state': 'Washington', 'country': 'United States', 'facility': 'Zain Research LLC', 'geoPoint': {'lat': 46.28569, 'lon': -119.28446}}], 'overallOfficials': [{'name': 'Ashika Ahmed, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Bellerophon Therapeutics'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bellerophon Pulse Technologies', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}